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Abstract: Obesity was commonly thought to be advantageous for maintaining healthy bones 
due to the higher bone mineral density observed in overweight individuals. However, several 
recent studies have challenged the widespread belief that obesity is protective against fracture 
and have suggested that obesity is a risk factor for certain fractures. The effect of obesity on 
fracture risk is site-dependent, the risk being increased for some fractures (humerus, ankle, 
upper arm) and decreased for others (hip, pelvis, wrist). Moreover, the relationship between 
obesity and fracture may also vary by sex, age, and ethnicity. Risk factors for fracture in obese 
individuals appear to be similar to those in nonobese populations, although patterns of falling 
are particularly important in the obese. Research is needed to determine if and how visceral fat 
and metabolic complications of obesity (type 2 diabetes mellitus, insulin resistance, chronic 
inflammation, etc) are causally associated with bone status and fragility fracture risk. Vitamin 
D deficiency and hypogonadism may also influence fracture risk in obese individuals. Fracture 
algorithms such as FRAX® might be expected to underestimate fracture probability. Studies 
specifically designed to evaluate the antifracture efficacy of different drugs in obese patients 
are not available; however, literature data may suggest that in obese patients higher doses of the 
bisphosphonates might be required in order to maintain efficacy against nonvertebral fractures. 
Therefore, the search for better methods for the identification of fragility fracture risk in the 
growing population of adult and elderly subjects with obesity might be considered a clinical 
priority which could improve the prevention of fracture in obese individuals.
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Introduction
Obesity and osteoporosis are two public health problems with an increasing 
prevalence and high impact on morbidity and mortality which, during the last two 
decades, have become major health threats worldwide.1–3 Osteoporosis is a systemic 
skeletal disease characterized by low bone mineral density (BMD) and microarchitec-
tural deterioration of bone tissue leading to an increased risk of developing spontaneous 
and traumatic bone fractures.3 The World Health Organization (WHO) defines obesity 
as abnormal or excessive fat accumulation that presents a risk for health. The body 
mass index (BMI) is a simple way of measuring the degree of obesity.4 WHO defines 
obesity as a BMI of 30 kg/m2, overweight as BMI 25–29.9 kg/m2, and underweight 
as BMI 18.5 kg/m2. 
Obesity, as defined according to WHO criteria, has more than doubled worldwide 
in the last 30 years. The prevalence of obesity in the US is estimated to be 34% and 
37% of women and men, respectively; whereas in Europe it is estimated to be 23% of 
women and 20% of men.1,2 The prevalence of obesity is destined to grow worldwide 
and, for example, it is projected that by 2025, 47% of men and 36% of women in the 
UK will be obese, carrying a highly elevated cost to the National Health Service.5,6 In 
addition, obese subjects present an increased risk of being affected by type 2 diabetes 
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mellitus, hypertension, dyslipidemia, and cardiovascular 
diseases, and also have an increased risk of developing some 
types of cancer. However, for many years body weight has 
been considered one of the important determinants of BMD 
and positive relationships between body weight and BMD, 
or between BMI and BMD have been reported.7 An inverse 
relationship between body weight or BMI and the risk of any 
fractures has also been shown.8 In particular, obese women 
have always been considered protected against osteopo-
rosis and osteoporotic fractures. However, in recent years 
the association between obesity and osteoporosis has been 
actively investigated from epidemiological, clinical, and 
basic research points-of-view, making it evident that osteo-
porosis and obesity can no longer be considered antithetic, 
instead they are closely connected and may present common 
pathophysiological mechanisms. Extensive epidemiological 
studies have reported that elevated body weight or BMI are 
positively correlated with increased BMD and with reduced 
risk of fragility fractures in both men and women.8 The 
generally accepted explanation of this relationship is that 
a larger body mass induces greater mechanical loading on 
bone, with a consequent increase in BMD to accommodate 
the greater load.8
Many studies have reported that in healthy premenopausal 
and postmenopausal women total body fat is positively 
related to BMD, which is commonly considered the most 
important measurable determinant of fracture risk, and that 
decreased body weight leads to bone loss.9–11 On this basis 
low body weight has been incorporated into the FRAX® 
and Garvan algorithms, calculations aimed to predict an 
individual’s prospective fracture risk. In recent years there 
has been a growing interest in studying the influence of body 
composition on bone status and in particular the relation-
ship between fat mass and BMD. The major mechanisms 
by which fat mass may influence bone tissue have recently 
been reviewed by several authors.9–11 Abundant fat mass 
might have several positive effects. Firstly, mechanical load-
ing stimulates bone formation by decreasing apoptosis and 
increasing proliferation and differentiation of osteoblasts and 
osteocytes through the Wnt/β-catenin signaling pathway.9,10 
Therefore, mechanical loading is the basis of the assumption 
that has led to the belief that obesity may prevent bone loss 
and osteoporosis.12,13 Moreover, abundant adipose tissue is 
considered an important source of estrogen production, by 
an increased aromatization of androgens to estrogens, and 
may contribute to increased BMD. On the other hand, the 
association between fat mass and BMD has been reported to 
be stronger in women than in men.13,14 Also, many hormones 
may link fat mass to bone tissue. An excess of fat mass is asso-
ciated with an increased secretion of insulin and amylin from 
pancreatic β-cells, decreased sex hormone binding globulin 
serum levels with increased levels of free sex steroids, and 
changes in the production of adipokines, among the more 
studied being leptin and adiponectin.9 Leptin, the most widely 
recognized adipocyte-derived hormone, is mainly known for 
its function of suppressing appetite and increasing energy 
expenditure, and is considered to play a crucial role in the 
protective effect of fat on bone. However, in vitro studies 
have recently confirmed that the effect of leptin on bone is 
complex and some cross-sectional studies assessing the role 
of leptin on BMD have reported both negative and positive 
effects.9,15,16 Adiponectin, an adipocyte-produced hormone 
that correlates negatively with obesity in general, and central 
adiposity in particular, has been reported to stimulate both 
bone formation and bone resorption, but its effect on BMD 
remains controversial.9,15,16 Recently, some studies, mainly by 
Chinese authors, have contributed to the clarification of these 
points.17–18 In a large-scale sample of Chinese and Caucasian 
subjects, Zhao et al17 found that there is a positive correlation 
between fat mass and bone mass in both sexes, when results 
are not corrected for the mechanical loading effect of body 
weight. However, when the mechanical loading effect caused 
by total body weight is statistically removed, both fat mass 
and percentage fat are negatively correlated with bone mass.17 
Consistent with this finding two more recent studies, carried 
out on large cohorts of Chinese and Korean subjects, found 
that subjects with a higher percentage of body fat presented 
lower BMD and a higher prevalence of osteoporosis.18,19 In the 
same period Premaor et al20 reported that, of postmenopausal 
women with low trauma fracture attending a Fracture Liaison 
Service in the UK over a 2-year period, 28% were obese, and 
that in the majority of these obese women BMD was in the 
normal range. More recently the Global Longitudinal study 
of Osteoporosis in Women (GLOW), a large multinational 
study of women aged 55 years, has reported similar rates 
of clinical fractures in obese and nonobese women, with 23% 
and 22% of all previous and incident fractures, respectively, 
occurring in obese women.21
Pathophysiology of bone  
fragility in obesity
In recent years there has been a growing interest in study-
ing the relationships between fat mass, BMD, and bone 
fragility. The possible mechanisms by which obesity may 
influence bone fragility and, consequently, fragility fracture 
risk are listed in Table 1. One possible mechanism may 
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be represented by the fact that obesity is now known as a 
systemic inflammatory condition and that adipose tissue 
secretes various inflammatory cytokines, mainly interleukin 
6 (IL-6) and tumor necrosis factor-α (TNF-α) which may 
upregulate the receptor activator of nuclear factor k ligands 
(RANKL), stimulating osteoclastogenesis and leading to 
bone resorption.10,22 Moreover, it has been reported that the 
production of proinflammatory cytokines is higher in abdomi-
nal fat than in subcutaneous fat, whereas aromatase activity 
and adiponectin secretion are lower in visceral than in subcu-
taneous fat.23,24 The proinflammatory cytokines are involved 
in the regulation of other adipokines, in particular, increased 
IL-6 and TNF-α production by adipose tissue was associ-
ated with a reduced production of adiponectin, an adipokine 
which seems to have a protective effect on bone.16 Moreover, 
increased IL-6 and TNF-α production by adipose tissue is 
associated with insulin resistance, type 2 diabetes mellitus, 
and atherosclerosis, pathological conditions that, in turn, 
could impair bone strength.24,25 Also, Amati et al reported that 
both lower thigh subcutaneous and higher visceral abdominal 
adipose tissue contribute to insulin resistance.26 At present, 
the association between insulin resistance and bone mass 
still remains unclear. Recent literature data have reported 
that although insulin is a potent regulator of bone growth and 
directly stimulates osteoblasts in vitro, the insulin resistance 
negatively influences bone status.9,11 In fact, in a nationally 
representative sample of Korean men, both insulin resis-
tance status and fasting serum insulin levels were inversely 
associated with bone mass.27 However, a study carried out 
by Choi et al28 on a large cohort of Korean and US subjects, 
has suggested that the adverse influence of insulin on bone 
mass likely reflects the effects of other factors associated with 
insulin resistance than being a direct action of insulin itself.28 
Moreover, high insulin levels might reduce the carboxylation 
of osteocalcin and increase RANKL production, so result-
ing in increased bone resorption.29 Recent evidence has also 
reported that obesity, and particularly abdominal obesity, 
is characterized by increased serum levels of C-reactive 
protein, an inflammatory marker which has been associated 
with lower BMD, higher levels of bone turnover markers 
and, more recently, greater risk of fracture, further suggest-
ing an important role of inflammation in bone impairment 
in obese subjects.10 In fact, high fat-induced obese animals 
exhibited increased bone marrow adiposity accompanied by 
upregulation of peroxisome proliferator-activated receptor 
gamma, IL-6, and TNF-α, and reduced BMD.30
It is well known that obesity is associated with reduced 
levels of 25-hydroxyvitamin D, and that fat mass and 
25-hydroxyvitamin D are inversely related. This has been 
attributed to sequestration of this fat-soluble vitamin in 
adipose tissue, though there is also evidence that vitamin D 
inhibits development of adipocytes.9,31 Moreover, it has been 
reported that parathyroid hormone (PTH) concentrations are 
directly correlated with fat mass and inversely associated with 
25-hdroxyvitamin D levels, whereas other studies did not find 
any relationship between PTH and 25-hydroxyvitamin D.31,32 
The increased levels of PTH may determine a greater impair-
ment of cortical bone and offer an explanation for the major 
prevalence of fractures in skeletal sites where cortical bone 
prevails such as the humerus, ankle, and upper arm.33
In males, obesity is considered an important risk factor for 
hypogonadism.34 Hypogonadism, obesity, erectile dysfunc-
tion, insulin resistance, and metabolic syndrome often coexist 
in the same subjects who are considered to be at increased risk 
of falls and fractures.34 Moreover, in some individuals there is 
an inverse association between accumulation of body fat and 
the decrease in muscle mass and/or function. This condition, 
termed “sarcopenic obesity”, probably due to proinflamma-
tory factors produced by adipose tissue, represents a further 
risk for falls and fractures.35 In fact, although greater soft 
tissue padding may reduce skeletal trauma following a fall, 
poorer protective responses to falling due to muscle weakness 
and the higher impact of the fall owing to high body weight 
may offset this potential benefit. Finally, a high-fat diet, 
often a cause of obesity, has been reported to interfere with 
intestinal calcium absorption. Free fatty acids can form unab-
sorbable, insoluble calcium soaps and therefore contribute 
to low calcium absorption.10 Furthermore, as the association 
between obesity and fractures is markedly influenced by sex, 
the studies reporting data on this point should be considered 
separately according to sex.
Obesity and fractures in 
postmenopausal women and in men
Many epidemiological studies have reported that low body 
weight and low BMI are risk factors for fragility fracture. 
Table 1 Potential pathogenetic mechanisms for fragility fractures 
in obese individuals
•	 Increased	production	of	proinflammatory	cytokines
• Insulin resistance
•	 Vitamin	D	deficiency
• Secondary hyperparathyroidism
• Hypogonadism
• Muscular impairment 
• Calcium malabsorption
• Comorbidities and comedications
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In particular, the results of a meta-analysis of 60,000 men and 
women from 12 prospective, population-based cohorts showed 
that total fractures, osteoporotic fractures, and hip fractures 
were all inversely correlated to BMI in both men and women, 
but these associations were lost after adjustment for BMD, 
with the exception of hip fracture.8 Moreover, in the study by 
Schott et al carried out on a large population of almost 8,000 
French women 75 years old, there was a 40% increase in hip 
fracture risk for each standard deviation decrease in fat mass, 
whereas the fracture risk was not influenced by lean mass.36 
The study by Premaor et al evaluated 1,005 postmenopausal 
women 75 years of age presenting to a Fracture Liaison 
Service in Cambridge (UK) with a low trauma fracture, and 
reported that fractures of the wrist were significantly less 
common and hip fractures significantly more common in 
obese compared to nonobese women.20 The GLOW study, a 
prospective cohort study involving 723 physician practices 
in ten countries, has reported that the risk of incident ankle 
and upper leg fractures was significantly higher in obese 
than nonobese women, while the risk of wrist fracture was 
significantly lower.21 A previous Italian study, carried out on 
2,235 Italian postmenopausal women with fracture, reported 
that increased BMI was associated with a significantly higher 
risk of humerus fracture and a lower risk of hip fracture, 
whereas no relationship was seen between BMI and either 
wrist or ankle fractures.37 Using data from the Womens’ Health 
Initiative (WHI) study in postmenopausal women, Beck et al 
reported that overweight and obese women presented a 
higher incidence of lower-extremity and a lower incidence 
of hip fractures with respect to normal weight women.38 
A recent prospective study by Prieto-Alhambra et al carried out 
on 832,775 Spanish women aged 50 years visiting general 
practitioners has confirmed that obesity is protective against 
hip and pelvis fractures, but is associated with an almost 20% 
increase in risk for proximal humerus fracture.39 Data on ver-
tebral fractures in obese subjects are scarce, although in an 
Italian study carried out on a small cohort of postmenopausal 
women higher BMI appeared to be associated with a higher 
likelihood of having vertebral fractures, irrespective of the 
positive association between weight and BMD.40
Some recent studies carried out on Korean, Australian, 
and Japanese postmenopausal women reported that obesity 
was associated with an increased risk of vertebral fractures, 
whereas another Australian study found a protective effect 
of abdominal fat on vertebral fractures in women, but not in 
men.19,41–43 A recent analysis using data from the Nottingham 
Fracture Liaison Service reported that obese subjects were 
more likely to fracture their ankle and upper arm, but were 
less likely to fracture their wrist.44 Also, two studies carried 
out in adult men and women reported that ankle fracture was 
significantly related to obesity.45,46 A prospective study by the 
Osteoporotic Fractures in Man Research Group reported that 
obesity was associated with an increased risk of nonvertebral 
fractures in men aged 65 years after adjustment for BMD, 
whilst in a large population-based study of Spanish men, an 
increase in multiple rib fractures was reported in overweight 
and obese men aged 65 years.47,48 Conversely, this latter 
study reported a protective effect of obesity for hip, wrist, 
and clinical spine fractures in elderly males.48 Tables 2 and 
3 summarize the results of the studies published in the last 
5 years.
At present, literature data suggest that in postmenopausal 
women obesity is associated with an increased risk in ankle, 
other lower limb, and humerus fractures, and a reduced risk 
Table 2 Obesity and fracture in men (2009–2014)
Reference Country Population Assessment  
of obesity
Increased  
fractures  
(skeletal sites)
Reduced  
fractures  
(skeletal sites)
Study  
characteristics
Nielson et al47 USA 5,995 men  
65 years
BMI Hip, non-spine – Longitudinal
Laslett et al41 Australia 489 men aged  
50–80 years
BMI, total fat, waist  
circumference
– vertebrae Cross-sectional
Premaor et al48 Spain 139,419 men  
65 years
BMI Rib Hip, spine, wrist/ 
forearm, pelvis
Cohort
Jordan et al46 Thailand 25,865 men aged  
19–49 years
BMI – – Cohort
Ong et al44 UK 722 men aged  
50–70 years
BMI Upper forearm,  
ankle
wrist Cross-sectional
Yang et al43 Australia 360 men  
50 years
Total and  
abdominal fat mass
– – Prospective
Abbreviation: BMI, body mass index.
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in hip, pelvis, and wrist fractures. In males, data are less 
available, however, it is possible to demonstrate a similar pat-
tern. Indeed, the reasons for site-specific differences in frac-
ture risk in obese compared with nonobese individuals have 
not yet been established. A number of factors could explain 
the site distribution of fractures. In fact, soft tissue padding 
may protect against pelvis and hip fractures in obese subjects. 
Obese subjects tend to fall backward or sideways rather than 
forward, and this, together with impaired protective reactions 
to falling, may protect the wrist from the impact. On the other 
hand, the additional body weight in obesity may increase the 
force of a fall beyond that which can be accommodated by 
the arm. To date, the reasons for increased fracture risk at 
ankle and leg in obese individuals still remain unclear, but it 
is possible that excessive stresses (introversion/extroversion 
and bending/torsion) are involved.11,49 In addition, reduced 
levels of 25-hydroxyvitamin D and the consequent higher 
serum PTH levels reported in obese individuals could have 
an adverse effect on cortical bone.31,33
Although some previous studies, generally carried out 
in Asian populations, have suggested an inverse association 
between visceral adipose tissue and BMD, the impact of 
regional fat distribution on BMD still remains controversial. 
The uncertainty in the literature may be due to the fact that 
the majority of studies were carried out using dual-energy 
X-ray absorptiometry technique which is not able to precisely 
distinguish between subcutaneous and visceral fat. The fact 
that most of the previously mentioned studies have been 
conducted on women of Asian origin may contribute to the 
uncertainty of literature data. In particular, it has been reported 
that for the same BMI, Asians had higher percentage body fat 
and abdominal obesity components, compared with those of 
Caucasian subjects, which may be deleterious for bone.50
Evaluation of fracture risk  
in obese subjects
The identification of patients with high fragility fracture risk 
before they have fractures might be considered a clinical prior-
ity which could improve the prevention of fractures. However, 
there is growing awareness of the inadequacy of current meth-
ods to predict fracture risk in obese patients, who constitute a 
substantial portion of the older population. In obese patients, 
laboratory assessment does not offer any extra information 
but is essential for a comprehensive evaluation of the fracture 
risk. In addition to standard laboratory tests, it is important to 
assess the level of glycemic control by blood glucose profiles 
and, HbA
1c
, the serum levels of 25-hydroxyvitamin D and to 
calculate the glomerular filtration rate. The measurement of 
Table 3 Obesity and fracture in women (2009–2014)
Reference Country Population Assessment  
of obesity
Increased  
fractures  
(skeletal sites)
Reduced  
fractures  
(skeletal sites)
Study  
characteristics
Compston et al21 UK 60,393 women  
55 years
BMI Upper	leg,	ankle wrist Longitudinal
Premaor et al20 UK 1,005 women  
75 years
BMI Hip wrist Cross-sectional
Gnudi et al37 Italy 2,235 PM women BMI Humerus Hip Cross-sectional
Beck	et	al38 USA 78,013 women  
aged 50–79 years
BMI Lower extremity Hip, vertebrae Longitudinal
Prieto-Alhambra et al39 Spain 832,775 women  
50 years
BMI Humerus Hip, pelvis Cross-sectional
Pirro et al40 Italy 362 PM women BMI vertebrae – Cross-sectional
Kim et al19 Korea 907 women aged  
50–80 years
BMI, waist  
circumference
vertebrae – Cross-sectional
Laslett et al41 Australia 522 women aged  
50–80 years
BMI, total fat, waist  
circumference
vertebrae – Cross-sectional
Tanaka	et	al42 Japan 1,614 postmenopausal  
women 50 years
BMI vertebrae Hip Longitudinal
Ong et al44 UK 3,566 women aged  
50–70 years
BMI Ankle,	upper	 
arm
wrist Cross-sectional
Jordan et al46 Thailand 32,339 women aged  
19–40 years
BMI Ankle,	leg – Cohort
Yang et al43 Australia 766 women  
50 years
Total and  
abdominal fat mass
– vertebrae Prospective
Abbreviations: BMI, body mass index; PM, postmenopausal.
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bone turnover markers, namely bone-specific alkaline phos-
phatase and Serum CrossLaps®, could be useful in differential 
diagnosis and for the monitoring of treatment response.
Although BMD is significantly higher in obese women 
with fractures than in their nonobese counterparts, obese 
women with fracture have a significantly lower BMD at 
both the lumbar spine and femoral neck when compared 
with women of similar age and weight without fractures.48 
These findings suggest that BMD may be inappropriately low 
in those obese subjects who fracture and also confirms the 
importance of BMD evaluation in obese individuals. How-
ever, since obese individuals generally have higher BMI and 
BMD, fracture algorithms such as FRAX might be expected 
to underestimate fracture probability. The predictive value 
of FRAX in obese older women who were participating in 
the Study of Osteoporotic Fractures study have been recently 
assessed by Premaor et al.51 In this latter study the 10-year 
probability of hip fracture was 10.9% and 7.1% in nonobese 
and obese postmenopausal women, respectively; whereas, the 
10-year probability of major osteoporotic fracture in nonobese 
and obese postmenopausal women was 23.3% and 18.2%, 
respectively.51 However, the area under the curve determined 
by receiver operating curve analysis was similar in nonobese 
and obese women.51 Therefore, the FRAX-based intervention 
thresholds (eg, 20% probability of a major osteoporotic 
fracture or 3% probability of hip fracture in the following 
10 years) are probably too high for obese patients and should 
be reduced. Unfortunately, at present no data are available to 
supply any information regarding the real necessity and the 
significance of such a reduction.11,49 Literature data suggest 
that poor metabolic health associated with obesity may impair 
bone strength and/or density; therefore, obese subjects with 
a waist circumference exceeding published cut-points, type 
2 diabetes, or insulin resistance may be at higher risk for fra-
gility fractures.49 However, at present, it is not known whether 
the incorporation of such parameters into the FRAX algorithm 
may ameliorate fracture prediction. Finally, X-ray evaluation 
of the thoracolumbar spine should be considered in case of 
progressive back pain, kyphosis, or substantial height loss to 
check for possible vertebral fractures. In fact, the presence 
of vertebral fractures may be expected to increase the risk of 
further vertebral, nonvertebral, and hip fractures.
Prevention of fragility fractures  
in obese subjects
Calcium and vitamin D supplementation
In obese patients, any deficiencies in calcium and vitamin D 
should be prevented and treated before specific osteoporosis 
drugs are started; however, at present there are no specific 
guidelines for calcium/vitamin D supplementation in obese 
patients. The National Institute of Health in the USA 
proposes a recommended dietary allowance for calcium 
of 1,000 mg in men aged 50–70 years, and 1,200 mg in 
men 70 years and women 50 years. The recommended 
daily calcium intake should ideally be reached through the 
diet, and calcium supplementation should be restricted to 
whenever the dietary intake is inadequate or, for whatever 
reason, cannot be optimized with diet. In fact, recent stud-
ies have reported that high doses of calcium supplementa-
tion may increase the deposit of calcium at the level of 
atherosclerotic plaques and may represent a risk factor for 
myocardial infarction and other cardiovascular diseases.52 
Vitamin D deficiency is common among elderly subjects 
and it is thought to contribute to bone loss by stimulating 
PTH secretion, with consequent increased bone resorp-
tion. Vitamin D supplementation should ensure serum 
25-hydroxyvitamin D levels of 75 nmol/L (=30 ng/mL), 
since previous studies have reported that bone mineraliza-
tion defects were not seen if serum 25-hydroxyvitamin 
D levels were 75 nmol/L.53 As the majority of subjects 
cannot reach the threshold of 30 ng/mL by consuming 
foods rich in vitamin D or sun exposure, a supplementation 
of 800–2,000 IU of vitamin D per day is recommended. 
Obese patients require higher doses of vitamin D (3,000 
IU daily) because of a larger volume of distribution and the 
accumulation of vitamin D in the adipose tissue. Since the 
adherence to daily regimens of vitamin D supplementation 
may be low, higher intermittent doses (25,000 IU monthly 
or 100,000 every 4 months) have been proposed, which 
should improve treatment adherence.54 However, recent 
studies reported that the use of vitamin D boluses exceeding 
100,000–300,000 IU may be associated with an unexpected 
increase in bone resorption and in fracture rate.55 The abil-
ity of vitamin D in reducing falls in the elderly has been 
observed in several studies and in a double-blind, random-
ized controlled trial by Bischoff et al56 carried out in a cohort 
of 122 elderly women without type 2 diabetes mellitus 
(mean age 85.3 years). In this study the participants were 
randomized to receive 1,200 mg calcium plus 800 IU 
cholecalciferol or 1,200 mg calcium per day over a 12-week 
treatment period. The results showed that the vitamin D plus 
calcium supplementation reduced the number of falls per 
person by 49%, improved musculoskeletal function, and 
decreased PTH levels and bone resorption markers. These 
findings support the necessity for all obese patients to have 
adequate serum levels of vitamin D assured.
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Pharmacological therapy 
In recent years the therapeutic alternatives for the prevention 
and treatment of osteoporotic fractures have notably increased 
in number, and today comprise numerous drugs with different 
mechanisms of action. However, studies specifically designed 
to evaluate the antifracture efficacy of different drugs in obese 
patients are not available and pivotal trials58–60 included 
relatively few obese individuals. In addition, a recent study 
carried out in the GLOW population reported that obese 
women with fracture are more frequently undertreated 
than those nonobese (27% versus 41%).57 At present, the 
only available data are those regarding anticatabolic drugs. 
In a study of the effects of clodronate in postmenopausal 
women, the reduction in nonvertebral fractures in obese 
women was not significant, whereas a significant reduction 
was observed in nonobese women.58 Moreover, the subgroup 
analyses of the HORIZON study and of the FREEDOM 
study reported that the reduction in vertebral fractures were 
similar in obese and nonobese osteoporotic women, whereas 
the reduction in nonvertebral fractures was significant only in 
those women with a BMI 25 kg/m2.58,60 These data, prob-
ably due to the small numbers of obese women enrolled in 
the studies, may suggest that higher doses of bisphosphonates 
in obese patients might be required in order to maintain the 
efficacy against nonvertebral fractures.59,60 At present no 
data exist in the literature regarding the efficacy of strontium 
ranelate and teriparatide in obese patients.
Conclusion
Even though the incidence and the pathogenesis of fracture 
in obese individuals have not yet been clearly defined, the 
growing evidence that obesity may be related to an increased 
risk of fracture has important public health implications. 
Therefore, the search for better methods for the identifica-
tion of fragility fracture risk in the growing population of 
adult and elderly subjects with obesity might be considered 
a clinical priority which could improve the prevention of 
fracture in these patients.
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